Robert Petit, Ph.D.

Chief Medical & Scientific Officer, Founding Scientist (OST-HER2)
Dr. Robert Petit is a seasoned biopharma executive and medical scientist who has held C-Suite roles across biotech, oncology, immunology, and infectious disease. Robert excels in corporate strategy, clinical and scientific development, and regulatory affairs.
See full team
Robert Petit
Background

Dr. Robert Petit is an accomplished biopharma executive, innovator/inventor, company builder, and medical scientist. His personal mission is to develop new products and treatments that improve and extend the lives of patients. Robert has C-Suite experience leading several public and private therapeutic companies in the biotechnology, oncology, immunology, and infectious disease spaces. He has a consistent track record of excellence in corporate strategy, clinical development, scientific development, pipeline determination, medical and regulatory affairs.

Our Pipeline

The Future of Cancer Treatment

OS Therapies is not just addressing Osteosarcoma. With the other uses of our HER2 target cancer immunotherapy and the addition of our OST-tADC tunable Antibody Drug Conjugate silicone linker platform, we are paving the way for the next-generation of cancer treatments.
Female chemist working on osteosarcoma treatments | OS TherapiesLab technician working on cancer treatments | OS TherapiesFemale chemist working on cancer treatments